Brand Name Manufacturers	Delatestryl by Bio-Technology
Generic Manufacturers	Barr Quality Care
Pharmacology	Apparently same as endogenous androgens
Delivery	100, 200mg/ml sustained-release intramuscular injection
Typical dosage	Pre-op 200-400mg/2wks Post-op 50-200mg/2wks
Availability	Approved by U.S. FDA. Schedule III controlled substance.
Indications	Breast cancer in females. Hormone replacement therapy in males.
Contraindications	Hypersensitivity to any component of the product. Kidney disease. Known or suspected breast cancer.
Adverse reactions	CNS Anxiety. Depression. Headache. Prickling or tingling skin. Gastrointestinal Cholestatic jaundice. Liver tumors and other liver disease. Nausea. Skin Acne. Male pattern baldness. Other Extreme allergic reaction. Increased serum cholesterol. Retention of sodium, chloride, water, potassium, calcium, and inorganic phosphates. Suppression of blood clotting factors.
Comments	The author sees nothing in the PDR that would make this drug inferior to testosterone cypionate, but the cypionate seems to be more popular. Schein/Steris has reportedly discontinued production of injectable testosterone. This action forced up the price of the supply from other manufacturers. See http://www.thegrid.net/ftminfnet/schein.htmlfor more information.
Additional Info:	None

<< RETURN TO SUMMARY